Akebia's chief commercial officer resigns, to stay on as consultant
Nicholas Grund will leave his post on November 6, 2026, then advise the company on an hourly basis through April 2027.
Akebia Therapeutics disclosed in an 8-K filed October 14, 2026 that Nicholas Grund, Senior Vice President and Chief Commercial Officer of the company, notified Akebia on October 7, 2026 of his decision to resign for personal reasons.1 His resignation takes effect on November 6, 2026.1
Following the resignation, Grund and Akebia signed a Consulting Agreement on October 13, 2026, effective as of his resignation date, under which he will provide consulting and advisory services to the company through April 30, 2027.1 The filing notes that the consulting period can end earlier if the company gives at least 10 days' written notice, or if Grund gives at least 30 days' notice.1
Under the terms disclosed, Grund will be paid an hourly rate for his services during the consulting period.1 The filing was signed by John P. Butler, President and Chief Executive Officer of Akebia, on October 14, 2026.1 No successor to the Chief Commercial Officer role was named in the filing.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.